AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:27 2024-04-23 am EDT			5-day change	1st Jan Change
11,268 ^GBX	+0.16%		+3.59%	+6.30%

03:38pm	AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder	MT
10:50am	ASTRAZENECA : JP Morgan reaffirms its Buy rating	ZD

ASTRAZENECA : UBS keeps a Sell rating

February 17, 2020 at 06:00 am EST

UBS analyst Michael Leuchten reiterate his Sell rating on the stock. The target price remains set at GBp 5800.

Latest news about AstraZeneca PLC

AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder	09:38am	MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating	04:50am	ZD
AstraZeneca: Voydeya approved in the EU as a treatment for HPN	04:12am	CF
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease	02:29am	MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations	Apr. 22	MT
AstraZeneca: presents new data at ECCMID	Apr. 17	CF
The market is pinning its hopes on earnings reports	Apr. 17
ASTRAZENECA : Receives a Buy rating from JP Morgan	Apr. 17	ZD
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean...	Apr. 17
Market sentiment sours	Apr. 16
ASTRAZENECA : Deutsche Bank returns to 'Hold	Apr. 16	CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT	Apr. 16	MT
Astrazeneca plc Announces IMFINZI Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial	Apr. 16	CI
ASTRAZENECA : Deutsche Bank drops its Sell rating	Apr. 16	ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca	Apr. 16
RBC raises Admiral; Barclays cuts Phoenix Group	Apr. 16	AN
AstraZeneca: improvements in biliary tract cancer	Apr. 16	CF
AstraZeneca's hails Imfinzi survival data on cancer form	Apr. 16	AN
AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial	Apr. 16	MT
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors	Apr. 15	CI
AstraZeneca: expects a sharp rise in kidney disease	Apr. 15	CF
ASTRAZENECA : Barclays reiterates its Buy rating	Apr. 15	ZD
Adherium’s Hailie Smartinhaler Secures FDA Approval for Use with AstraZeneca's Airsupra and Breztri Inhalation Devices	Apr. 14	MT
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...	Apr. 12
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	Apr. 12	DJ

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

138.8 USD

Average target price

161.7 USD

Spread / Average Target

+16.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+6.30%	215B
ELI LILLY AND COMPANY	+27.23%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.23%	359B
MERCK & CO., INC.	+16.41%	322B
ABBVIE INC.	+9.78%	297B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.87%	149B
AMGEN INC.	-4.92%	146B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : UBS keeps a Sell rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals